Clinical trials: Venous Thromboembolism
Arterial Thromboembolism, Venous Thromboembolism
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
The objective of this study is to characterize and compare the risks of long-term use of oral contraceptives containing drospirenone and of other established oral contraceptives.
- Conditions
- Arterial Thromboembolism, Venous Thromboembolism, Breast Cancer
- Trial name
- NCT00676065
- Where
- Germany
- Volunteers
- 58,303 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Venous Thromboembolism, Deep Venous Thrombosis
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant…
- Trial name
- NCT07399977
- Testing
- MSK-ACCESS, ctDNA/VTE Risk Score:
- Where
- 8 sites in United States, Australia
- Volunteers
- 259 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Venous Thromboembolic Event
Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management
This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients
- Trial name
- NCT07464808
- Testing
- follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay, follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome
Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years. Reduce the risk of recurrence is a serious public health issue.
- Trial name
- NCT02904967
- Testing
- Extra Blood Draw
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Deep Venous Thromboses, Pulmonary Embolism
ThRombosis ExclUsion STudy
Primary objective: To demonstrate the ability of STA® - Liatest® D-Di XL combined with a clinical PreTest Probability (PTP) to safely exclude pulmonary embolism (PE) and deep venous thrombosis (DVT) as measured by Negative…
- Conditions
- Deep Venous Thromboses, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- TRUST (NCT03477968)
- Testing
- DDimer test
- Where
- 20 sites in United States, Belgium and 3 more
- Volunteers
- 5,935 people
- Sponsor
- Diagnostica Stago
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD
Atrial Fibrillation, Cardiac Thrombus
VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
The investigators aimed to use pharmacogenetic information in clinical practise which may lead to rapid, efficient, and safe warfarin dosing in this observational prospective study.
- Conditions
- Atrial Fibrillation, Cardiac Thrombus, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT00970892
- Testing
- Warfarin dose titration
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- Ankara University
Total Knee Replacement, Total Hip Replacement
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs.
- Trial name
- NCT00074828
- Testing
- LY517717, enoxaparin
- Where
- 8 sites in Australia, Austria and 6 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo
Delirium, Confusion
Improving Safety of Diagnosis and Therapy in the Inpatient Setting
To improve the safety of diagnosis and therapy for a set of conditions and undifferentiated symptoms for hospitalized patients, the investigators will employ a set of methods and tools from the disciplines of systems engineering…
- Conditions
- Delirium, Confusion, Mental Status Change, Back Pain
- Trial name
- PSLL2-0 (NCT04393909)
- Testing
- Diagnostic Uncertainty Educational Curriculum, Diagnostic Timeout, Patient Diagnostic (Dx) Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Brigham and Women's Hospital
Embolism, Pulmonary
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
The primary objective is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and Deep Vein Thrombosis [DVT])) and safety of GSK576428 as…
- Trial name
- NCT00981409
- Testing
- Fondaparinux sodium, unfractionated heparin (UFH)
- Where
- 27 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Myotonic Dystrophy 1
Venous Thromboembolism in Myotonic Dystrophy Type 1
Investigators identified a high risk of deep vein thrombosis and pulmonary embolism in patients presenting myotonic dystrophy type 1 treated in our hospital, 10 times higher than general population matched on age and sex.
- Trial name
- DM1-VTE (NCT03424460)
- Testing
- Haemostasis tests, Monocytes and megacaryocytes culture and RNA extraction, RNA extraction
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolism
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.
- Trial name
- NCT00523614
- Where
- Germany
- Volunteers
- 3,400 people
- Sponsor
- Center for Epidemiology and Health Research, Germany
Venous Thromboembolism, Deep Vein Thrombosis
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
The protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- GARFIELD-VTE (NCT02155491)
- Where
- United States
- Volunteers
- 10,679 people
- Sponsor
- Thrombosis Research Institute
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate in Adolescents
To investigate the safety and tolerability of dabigatran etexilate capsules in a small group of eight adolescent patients.
- Trial name
- NCT00844415
- Testing
- dabigatran etexilate
- Where
- 2 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism, Contraception
Longitudinal Hemostatic Profile After Stopping Estroprogestative Contraceptives
This prospective cohort evaluates the longitudinal profile of hemostatic biomarkers during the first 3 months after having stopped a combined oral contraceptive.
- Trial name
- PILL-OFF (NCT03949985)
- Testing
- Tests of biological hemostatic profile associated with contraceptives
- Where
- Switzerland
- Volunteers
- 103 people
- Sponsor
- University Hospital, Geneva
Cerebral Venous Thrombosis
Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study
The objective of this retrospective, prospective, multicenter cohort study is to determine the risk factors for deterioration of CVT patients after admission and establish a scoring model for risk stratification of patients.
- Trial name
- NCT06266585
- Where
- China
- Volunteers
- 273 people
- Sponsor
- Beijing Tiantan Hospital
Venous Thromboembolism, Pulmonary Thromboembolisms
Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management.
- Conditions
- Venous Thromboembolism, Pulmonary Thromboembolisms, Digital Health
- Trial name
- SmaPE (NCT06382038)
- Testing
- mobile venous thromboembolism application (mVTEA)
- Where
- China
- Volunteers
- 2,972 people
- Sponsor
- Navy General Hospital, Beijing
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong